Prognostic biomarkers in acute coronary syndrome

Annals of Translational Medicine

Volumn 4, Issue 13, 2016, Pages

  Luca Salvagno, Gian ^a   Pavan, Chiara ^b  

^a UNIVERSITY OF VERONA   (Italy)

^b Mater Salutis Hospital   (Italy)

Author keywords

Acute coronary syndrome (ACS); Galectin 3 (GAL 3); Growth differentiation factor 15 (GDF 15); Prognostic biomarkers; Suppression of tumorigenicity 2 (ST 2)

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; ENKEPHALINASE INHIBITOR; GALECTIN 3; GROWTH DIFFERENTIATION FACTOR 15; INTERLEUKIN 1 RECEPTOR; SUPPRESSION OF TUMORIGENICITY 2; TROPONIN; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ADVERSE OUTCOME; ANEURYSM; CARDIOGENIC SHOCK; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CONGESTIVE HEART FAILURE; HEART ARRHYTHMIA; HEART FAILURE; HEART MUSCLE FIBROSIS; HEART RUPTURE; HEART VENTRICLE THROMBOSIS; HUMAN; LABORATORY TEST; MITRAL VALVE DISEASE; NONHUMAN; PREDICTIVE VALUE; PROGNOSIS; PROTEIN DETERMINATION; RELIABILITY; REVIEW;

EID: 85006207167     PISSN: 23055839     EISSN: 23055847     Source Type: Journal    
DOI: 10.21037/atm.2016.06.36     Document Type: Review

References (58)

1. Lippi G, Filippozzi L, Salvagno GL, et al. Increased mean platelet volume in patients with acute coronary syndromes. Arch Pathol Lab Med 2009;133:1441-3.
2. GoffDC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129:S49-73.
3. Siemelink MA, Zeller T. Biomarkers of coronary artery disease: the promise of the transcriptome. Curr Cardiol Rep 2014;16:513.
4. Lippi G. Biomarkers: Novel troponin immunoassay for early ACS rule-out. Nat Rev Cardiol 2016;13:9-10.
5. Lippi G, Franchini M, Cervellin G. Diagnosis and management of ischemic heart disease. Semin Thromb Hemost 2013;39:202-13.
6. Cervellin G, Mattiuzzi C, Bovo C, et al. Diagnostic algorithms for acute coronary syndrome-is one better than another? Ann Transl Med 2016;4:193.
7. Lippi G, Cervellin G. Risk assessment of post-infarction heart failure. Systematic review on the role of emerging biomarkers. Crit Rev Clin Lab Sci 2014;51:13-29.
8. Casagranda I, Cavazza M, Clerico A, et al. Proposal for the use in emergency departments of cardiac troponins measured with the latest generation methods in patients with suspected acute coronary syndrome without persistent ST-segment elevation. Clin Chem Lab Med 2013;51:1727-37.
9. Lippi G. Biomarkers of myocardial ischemia in the emergency room: cardiospecific troponin and beyond. Eur J Intern Med 2013;24:97-9.
10. Lippi G, Salvagno GL, Robuschi F, et al. Influence of dipyridamole stress echocardiography on galectin-3, amino-terminal B-type natriuretic peptide (NT-proBNP) and high-sensitivity troponin T. Acta Cardiol 2014;69:377-83.
11. Krześlak A, Lipińska A. Galectin-3 as a multifunctional protein. Cell Mol Biol Lett 2004;9:305-28.
12. Houzelstein D, Gonçalves IR, Fadden AJ, et al. Phylogenetic analysis of the vertebrate galectin family. Mol Biol Evol 2004;21:1177-87.
13. de Boer RA, Yu L, van Veldhuisen DJ. Galectin-3 in cardiac remodeling and heart failure. Curr Heart Fail Rep 2010;7:1-8.
14. Chen SC, Kuo PL. The Role of Galectin-3 in the Kidneys. Int J Mol Sci 2016;17.
15. Drickamer K, Taylor ME. Biology of animal lectins. Annu Rev Cell Biol 1993;9:237-64.
16. Kasai K, Hirabayashi J. Galectins: a family of animal lectins that decipher glycocodes. J Biochem 1996;119:1-8.
17. Cooper DN. Galectinomics: finding themes in complexity. Biochim Biophys Acta 2002;1572:209-31.
18. Barondes SH, Castronovo V, Cooper DN, et al. Galectins: a family of animal beta-galactoside-binding lectins. Cell 1994;76:597-8.
19. Ochieng J, Furtak V, Lukyanov P. Extracellular functions of galectin-3. Glycoconj J 2004;19:527-35.
20. Newlaczyl AU, Yu LG. Galectin-3--a jack-of-all-trades in cancer. Cancer Lett 2011;313:123-8.
21. Liu FT, Rabinovich GA. Galectins: regulators of acute and chronic inflammation. Ann N Y Acad Sci 2010;1183:158-82.
22. Salvagno GL, Schena F, Gelati M, et al. The concentration of high-sensitivity troponin I, galectin-3 and NT-proBNP substantially increase after a 60-km ultramarathon. Clin Chem Lab Med 2014;52:267-72.
23. Elola MT, Wolfenstein-Todel C, Troncoso MF, et al. Galectins: matricellular glycan-binding proteins linking cell adhesion, migration, and survival. Cell Mol Life Sci 2007;64:1679-700.
24. Takenaka Y, Fukumori T, Raz A. Galectin-3 and metastasis. Glycoconj J 2004;19:543-9.
25. Lippi G, Cervellin G, Sanchis-Gomar F. Galectin-3 in atrial fibrillation: Simple bystander, player or both? Clin Biochem 2015;48:818-22.
26. Ho JE, Gao W, Levy D, et al. Galectin-3 is Associated with Restrictive Lung Disease and Interstitial Lung Abnormalities. Am J Respir Crit Care Med 2016;194:77-83.
27. Sharma UC, Pokharel S, van Brakel TJ, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004;110:3121-8.
28. McCullough PA. Practical experience using galectin-3 in heart failure. Clin Chem Lab Med 2014;52:1425-31.
29. Meijers WC, van der Velde AR, Pascual-Figal DA, et al. Galectin-3 and post-myocardial infarction cardiac remodeling. Eur J Pharmacol 2015;763:115-21.
30. Suarez G, Meyerrose G. Heart failure and galectin 3. Ann Transl Med 2014;2:86.
31. Ho JE, Liu C, Lyass A, et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol 2012;60:1249-56.
32. Winter MP, Wiesbauer F, Alimohammadi A, et al. Soluble galectin-3 is associated with premature myocardial infarction. Eur J Clin Invest 2016;46:386-91.
33. Writing Committee Members, Yancy CW, Jessup M, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013;128:e240-327.
34. Tsai TH, Sung PH, Chang LT, et al. Value and level of galectin-3 in acute myocardial infarction patients undergoing primary percutaneous coronary intervention. J Atheroscler Thromb 2012;19:1073-82.
35. Maiolino G, Rossitto G, Pedon L, et al. Galectin-3 predicts long-term cardiovascular death in high-risk patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2015;35:725-32.
36. Lippi G, Salvagno GL, Bonfanti L, et al. Relationship between serum galectin-3 values and demographical or biochemical variables in patients without acute coronary syndrome. Int J Cardiol 2014;171:270-1.
37. Falcone C, Lucibello S, Mazzucchelli I, et al. Galectin-3 plasma levels and coronary artery disease: a new possible biomarker of acute coronary syndrome. Int J Immunopathol Pharmacol 2011;24:905-13.
38. Gucuk Ipek E, Akin Suljevic S, Kafes H, et al. Evaluation of galectin-3 levels in acute coronary syndrome. Ann Cardiol Angeiol (Paris) 2016;65:26-30.
39. Singsaas EG, Manhenke CA, Dickstein K, et al. Circulating Galectin-3 Levels Are Increased in Patients with Ischemic Heart Disease, but Are Not Influenced by Acute Myocardial Infarction. Cardiology 2016;134:398-405.
40. Mueller T, Jaffe AS. Soluble ST2--analytical considerations. Am J Cardiol 2015;115:8B-21B.
41. Klemenz R, Hoffmann S, Werenskiold AK. Serum- and oncoprotein-mediated induction of a gene with sequence similarity to the gene encoding carcinoembryonic antigen. Proc Natl Acad Sci U S A 1989;86:5708-12.
42. Mueller T, Dieplinger B. The Presage(®) ST2 Assay: analytical considerations and clinical applications for a high-sensitivity assay for measurement of soluble ST2. Expert Rev Mol Diagn 2013;13:13-30.
43. Weinberg EO, Shimpo M, De Keulenaer GW, et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 2002;106:2961-6.
44. Demyanets S, Speidl WS, Tentzeris I, et al. Soluble ST2 and interleukin-33 levels in coronary artery disease: relation to disease activity and adverse outcome. PLoS One 2014;9:e95055.
45. Dieplinger B, Egger M, Haltmayer M, et al. Increased soluble ST2 predicts long-term mortality in patients with stable coronary artery disease: results from the Ludwigshafen risk and cardiovascular health study. Clin Chem 2014;60:530-40.
46. Dhillon OS, Narayan HK, Khan SQ, et al. Pre-discharge risk stratification in unselected STEMI: is there a role for ST2 or its natural ligand IL-33 when compared with contemporary risk markers? Int J Cardiol 2013;167:2182-8.
47. Sabatine MS, Morrow DA, Higgins LJ, et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation 2008;117:1936-44.
48. Kohli P, Bonaca MP, Kakkar R, et al. Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. Clin Chem 2012;58:257-66.
49. Eggers KM, Armstrong PW, CaliffRM, et al. ST2 and mortality in non-ST-segment elevation acute coronary syndrome. Am Heart J 2010;159:788-94.
50. Ago T, Sadoshima J. GDF15, a cardioprotective TGF-beta superfamily protein. Circ Res 2006;98:294-7.
51. Kempf T, Eden M, Strelau J, et al. The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res 2006;98:351-60.
52. Ek WE, Hedman ÅK, Enroth S, et al. Genome-wide DNA methylation study identifies genes associated with the cardiovascular biomarker GDF-15. Hum Mol Genet 2016;25:817-27.
53. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000;342:1350-8.
54. Brown DA, Breit SN, Buring J, et al. Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study. Lancet 2002;359:2159-63.
55. Hagström E, James SK, Bertilsson M, et al. Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study. Eur Heart J 2016;37:1325-33.
56. Dominguez-Rodriguez A, Abreu-Gonzalez P, Avanzas P, et al. Effect of Serum Growth Differentiation Factor-15 and the Syntax Score on 2-Year Outcomes in Patients With Acute Coronary Syndrome. Am J Cardiol 2016;117:1569-74.
57. Wollert KC, Kempf T, Lagerqvist B, et al. Growth differentiation factor 15 for risk stratification and selection of an invasive treatment strategy in non ST-elevation acute coronary syndrome. Circulation 2007;116:1540-8.
58. Lippi G, Sanchis-Gomar F. Monitoring B-type natriuretic peptide in patients undergoing therapy with neprilysin inhibitors. An emerging challenge? Int J Cardiol 2016;219:111-4.